CicloMed Announces Initiation of Phase 1B Trial of Fosciclopirox in Newly Diagnosed and Recurrent Urothelial Cancer Patients

NEXT STORY
HiberCell Appoints Mark J. Mulvihill, Ph.D., Chief Scientific Officer
PREV STORY
Global Over the Counter and Direct to Consumer Infectious Disease Diagnostics Market Forecasts to 2024
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Conference call regarding Elekta’s Interim Report for May-January 2015/16

STOCKHOLM, February 17 – Elekta (EKTA-B.ST) will publish its interim report for May-January 2015/16 ...

author_avatar
NASDAQ Market News

Victoza® approved in the US as the only type 2 diabetes treatment indicated to reduce the risk of major adverse cardiovascular events

Bagsværd, Denmark, 25 August 2017 - The U.S. Food and Drug Administration (FDA) has ...

author_avatar
NASDAQ Market News

CRISPR Therapeutics Appoints Dr. Tony W. Ho to Head Research & Development

ZUG, Switzerland and CAMBRIDGE, Mass., Aug. 01, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), ...

author_avatar
NASDAQ Market News